Peter Svennilson
Managing Partner and Founder @ The Column Group
San Francisco, United States
Peter Svennilson is a Series B investor at The Column Group in San Francisco focused on Biotechnology and Health Care. Peter Svennilson is the Managing Partner and Founder of The Column Group, a biotech VC fund based in San Francisco. He has 23 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helpedfound companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Aragon Pharmaceuticals and PTC Therapeutics and has served on the Boards of Directors of several other biotechnology companies, including Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.
- Total investments:
- 18
- Last investment:
- Lead investor:
- 61%
Last updated:
For AI agents: llms.txt
Industries Peter Svennilson invests in
Stages Peter Svennilson invests in
Countries Peter Svennilson invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 6 (33%)
- Health Care 5 (28%)
- Therapeutics 5 (28%)
- Medical 2 (11%)
- Genetics 1 (6%)
Stage
- Series B 5 (28%)
- Series D 4 (22%)
- Series A 3 (17%)
- Series C 2 (11%)
- Series E 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Circle Pharma
|
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $90M / Series D / Sep 03, 2024 | |
NGM Biopharmaceuticals
|
NGM Biopharmaceuticals is a privately-held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic andcardiovascular diseases. The company's current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery. | $122M / Series A / Jul 17, 2024 | |
Remix Therapeutics
|
Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways. | $60M / Venture - Series Unknown / Jan 03, 2024 | |
Carmot Therapeutics
|
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $150M / Series E / May 25, 2023 | |
|
Carmot Therapeutics
|
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $160M / Series D / Jul 26, 2022 | |
|
Circle Pharma
|
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $66M / Series C / Jun 16, 2021 | |
|
Carmot Therapeutics
|
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $47M / Series C / Sep 30, 2020 | |
|
Circle Pharma
|
Circle Pharma is an early-stage biotechnology company applying proprietary computational design algorithms and innovative chemistry to develop cell-permeable macrocycle peptide therapeutics against important clinical targets. It does this through an iterative, rational design process that deploys large virtual libraries of conformationally diversemacrocycle scaffolds selected for inherent permeability. The company was founded by Matt Jacobson and Scott Lokey in 2012 and is headed by David J. Earp. | $45M / Series B / Mar 17, 2020 | |
|
Carmot Therapeutics
|
Carmot Therapeutics, Inc. provides drugs to treat inflammatory, metabolic, and neurological diseases. The company was founded in 2008 and is based in San Francisco, California. | $15M / Series B / Jan 17, 2018 | |
Gritstone bio
|
Gritstone Oncology is a clinical-stage biotech company developing tumor-specific cancer immunotherapies to fight multiple cancer types. Its approach seeks to generate a therapeutic immune response by leveraging insights into the immune system’s ability to recognize and destroy tumor cells by targeting tumor-specific neoantigens. GritstoneOncology is headquartered in Emeryville, California, with key functions located in Cambridge, Massachusetts, and Pleasanton, California. It was founded in August 2015 and is listed on the Nasdaq Global Select Market under the ticker symbol GRTS. | $93M / Series B / Sep 07, 2017 | |
| See all 18 investments → | |||
Co-Investors
About The Column Group
The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.
The Column Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Goeddel
Managing Partner
|
|||
Jeff Goater
Venture Partner
|
|||
Joseph Goldstein
Science Partner
|
|||
Millie Ray
Partner
|
|||
|
Peter Svennilson
Managing Partner and Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Svennilson invest in?
Peter Svennilson invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series D stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Peter Svennilson?
Public channels for Peter Svennilson include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Peter Svennilson last invest?
The most recent investment recorded for Peter Svennilson closed in Sep 2024. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
